CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)
32.48
0.00 (0.00%)
USD |
NASDAQ |
Mar 25, 16:00
CymaBay Therapeutics Research and Development Expense (Quarterly): 22.75M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.75M |
| September 30, 2023 | 19.96M |
| June 30, 2023 | 19.54M |
| March 31, 2023 | 18.55M |
| December 31, 2022 | 16.23M |
| September 30, 2022 | 15.46M |
| June 30, 2022 | 17.89M |
| March 31, 2022 | 18.42M |
| December 31, 2021 | 18.40M |
| September 30, 2021 | 17.01M |
| June 30, 2021 | 16.74M |
| March 31, 2021 | 12.38M |
| December 31, 2020 | 10.69M |
| September 30, 2020 | 7.743M |
| June 30, 2020 | 7.942M |
| March 31, 2020 | 9.509M |
| December 31, 2019 | 20.94M |
| September 30, 2019 | 23.19M |
| June 30, 2019 | 21.12M |
| March 31, 2019 | 18.59M |
| December 31, 2018 | 16.40M |
| September 30, 2018 | 17.85M |
| Date | Value |
|---|---|
| June 30, 2018 | 14.40M |
| March 31, 2018 | 9.477M |
| December 31, 2017 | 6.669M |
| September 30, 2017 | 4.184M |
| June 30, 2017 | 4.044M |
| March 31, 2017 | 4.041M |
| December 31, 2016 | 3.848M |
| September 30, 2016 | 3.534M |
| June 30, 2016 | 4.131M |
| March 31, 2016 | 4.428M |
| December 31, 2015 | 4.051M |
| September 30, 2015 | 4.528M |
| June 30, 2015 | 4.26M |
| March 31, 2015 | 4.187M |
| December 31, 2014 | 5.277M |
| September 30, 2014 | 3.848M |
| June 30, 2014 | 4.083M |
| March 31, 2014 | 2.615M |
| December 31, 2013 | 1.363M |
| September 30, 2013 | 0.703M |
| June 30, 2013 | 0.969M |
| March 31, 2013 | 1.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.743M
Minimum
Sep 2020
23.19M
Maximum
Sep 2019
16.55M
Average
17.89M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences Inc | 3.95B |
| Assure Holdings Corp | -- |
| Societal CDMO Inc (DELISTED) | -- |
| AN2 Therapeutics Inc | 14.92M |
| Madrigal Pharmaceuticals Inc | 70.64M |